Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 19.55 USD -0.46% Market Closed
Market Cap: 393.5m USD

Simulations Plus Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Simulations Plus Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Cash from Operating Activities
$18.1m
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
10%
Veeva Systems Inc
NYSE:VEEV
Cash from Operating Activities
$1.4B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
34%
Inspire Medical Systems Inc
NYSE:INSP
Cash from Operating Activities
$133.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Cash from Operating Activities
$273.3m
CAGR 3-Years
29%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Cash from Operating Activities
$153.3m
CAGR 3-Years
41%
CAGR 5-Years
1%
CAGR 10-Years
15%
W
Waystar Holding Corp
NASDAQ:WAY
Cash from Operating Activities
$169.8m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
393.7m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
HIDDEN
Show

See Also

What is Simulations Plus Inc's Cash from Operating Activities?
Cash from Operating Activities
18.1m USD

Based on the financial report for Aug 31, 2025, Simulations Plus Inc's Cash from Operating Activities amounts to 18.1m USD.

What is Simulations Plus Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was 36%.

Back to Top